Qishen Yiqi Dripping Pill Protects Against Diabetic Nephropathy by Inhibiting the Wnt/β-Catenin and Transforming Growth Factor-β/Smad Signaling Pathways in Rats

Qian Zhang, Xinhua Xiao*, Jia Zheng, Ming Li, Miao Yu, Fan Ping, Tong Wang and Xiaojing Wang

Key Laboratory of Endocrinology, Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China

Diabetic nephropathy is a severe microvascular complication of diabetes. Qishen Yiqi dripping pill (QYDP) has been reported to be a renal protective drug. However, the mechanisms remain unclear. This study was performed to investigate the mechanisms. In this study, Sprague-Dawley rats were injected with streptozotocin to generate a diabetes model. Diabetic rats were administered 150 or 300 mg/kg/day QYDP. After 8 weeks of treatment, serum creatinine, serum blood urea nitrogen, and 24-h urinary albumin were measured. Kidney histological staining and immunostaining were analyzed. Then, the renal tissue was analyzed with a genome expression array. The results showed that QYDP treatment reduced serum creatinine, blood urea nitrogen, and 24-h urinary albumin and improved kidney histology and fibrosis. The gene array revealed that the expression of 189 genes was increased, and that of 127 genes was decreased in the high dosage QYDP group compared with the diabetic group. Pathway and gene ontology analyses showed that the differentially expressed genes were involved in the Wnt/β-catenin and transforming growth factor-β (TGF-β)/Smad2 signaling pathways. QYDP reduced the renal Wnt1, catenin β1, Tgfb1, and Smad2 gene expression and β-catenin, TGF-β, Smad2, collagen I, α-smooth muscle actin, and fibronectin protein expression in diabetic rats. Our results provide the first evidence that QYDP performs its renal-protective function by inhibiting the Wnt/β-catenin and TGF-β/Smad2 signaling pathways in diabetic rats.

Keywords: TGF-β, Smad, β-catenin, diabetic nephropathy, Wnt

INTRODUCTION

In 2019, the International Diabetes Federation announced that diabetes affects approximately 463 million people worldwide. The number of affected individuals will reach 702 million by the year 2045 (Williams et al., 2020). Chronic tissue complications from diabetes worsen the health status of patients. Diabetic nephropathy (DN) is one of the most important microvascular complications. It
is estimated that more than 20% of diabetic patients will develop chronic kidney disease (CKD) (Nelson et al., 1996). Nephropathy contributes to the development of cardiovascular disease, resulting in increased all-cause mortality (Go et al., 2004).

The pathological characteristics of DN include the accumulation of extracellular matrix (ECM) in the glomerulus and tubules of the kidney, which leads to proteinuria and renal failure. Several pathways have been implicated in the underlying mechanisms of DN progression, such as oxidative stress (Baynes, 1991), inflammation (Mariappan, 2012), accumulation of advanced glycation end products (AGEs) (Brownlee et al., 1988), activation of protein kinase C (Koya et al., 1997), reactive oxygen species (Ha et al., 2008), and endoplasmic reticulum (ER) stress (Cybulsky et al., 2011).

Qishen Yiqi dripping pill (QYPD) is a traditional Chinese medicine compound that comprises Radix Astragali (Astragalus penduliflorus Lam.), redroot sage (Salvia miltiorrhiza Bunge), pseudoginseng (Panax pseudoginseng Wall.), and fragrant rosewood (Dalbergia odorifera T.C. Chen). QYPD is approved by the State Food and Drug Administration of China (state medical license no. Z20030139). A clinical trial showed that QYPD treatment reduced the urinary albumen excretion rate in diabetic patients (Yongbin Chen, 2011). QYPD intervention attenuated renal interstitial fibrosis in CKD model rats induced by unilateral ureteral obstruction surgery (Zhou et al., 2016). However, little is known about the mechanism of QYPD in the diabetic model.

The systematic principle of Chinese medicine raises the theory that traditional Chinese medicines have the integrated functions of all their constituents. Thus, we hypothesized that QYPD has multiple targets in the kidney and moderates the kidney function in diabetic rats. To identify these pathways, we used a genomewide array approach to analyze gene expression changes in the kidney and pathway analysis to gain deep insight into the gene expression alternations.

MATERIALS AND METHODS

Medicine
Qishen Yiqi dripping pill contains Radix Astragali (A. penduliflorus Lam., 62.24%), redroot sage (S. miltiorrhiza Bunge, 31.12%), pseudoginseng (P. pseudoginseng Wall., 6.22%), and fragrant rosewood (D. odorifera T.C. Chen, 0.42%). QYPD was provided by Tasly Pharmaceutical Group Co., Ltd. (Tianjin, China). All voucher specimens (no. QYPD19A-QYPD19D) were deposited at the Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China. Detailed information about the four herbs is presented in Supplementary Table 1. The quality of the herbs and herbal extracts was consistent with the standards of Chinese Pharmacopoeia (2015). The four-component herbs, Radix Astragali (1,800 g), redroot sage (900 g), pseudoginseng (180 g), and fragrant rosewood (12 g), were soaked in 60% ethanol for 1 h and extracted twice by refluxing for 2 h. The condensed extracts were mixed with dextrin and sugar powder to produce QYPD.

Ultra-Performance Liquid Chromatography Analysis of Qishen Yiqi Dripping Pill
Qishen Yiqi dripping pill powder (0.3 g) was dissolved in methanol and then filtered through a 0.22-µm filter membrane. QYPD was characterized using a Waters Acquity Ultra-Performance Liquid Chromatography (UPLC) (Waters Corp., Milford, MA, United States) with a symmetrical C18 column (100 × 2.1 mm i.d., particle size 1.7 μm, Waters Corp., Milford, MA, United States). The column was eluted at 30°C with a detection wavelength of 203 nm and an injection volume of 2 μl. The flow rate of the mobile phase of acetonitrile (A) and water (B) was set at 0.2 ml/min. Gradient separation was based on the following: 0–2 min, 15% A; 2–3 min, 15–18% A; 3–10 min, 18–20% A; 10–12 min, 20–25% A; 12–13.5 min, 25–34% A; 13.5–19 min, 34% A; 19–19.1 min, 34–90% A; 22–22.1 min, 90–15% A, 22.1–25 min, 15% A.

Animal Treatments and Diet
A total of twenty four 5-week-old male Sprague-Dawley (SD) rats were purchased from the Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China and provided with a standard diet and water. The rats were kept under a 12-h light/12-h dark cycle and at 24°C. This study was conducted in strict accordance with the recommendations and with the approval of the Animal Care Committee of the Peking Union Medical Hospital Animal Ethics Committee (Project XHDW-2015-0051, 15 February 2015), and all efforts were made to minimize suffering. Diabetes was induced by injection of streptozotocin (Sigma-Aldrich, St. Louis, MO, United States) at a dose of 60 mg/kg body weight. The rats with fasted blood glucose levels > 11.1 mmol/L were considered diabetic. Diabetic rats were divided into three groups: a vehicle-treated group [diabetes mellitus (DM) group, n = 6], low dosage of Qishen Yiqi dripping pill group (n = 6), and high dosage of Qishen Yiqi dripping pill group (HQYPD group, n = 6). The typical human daily dose of QYPD is 1.5 g per 60 kg of body weight. Thus, according to the formula $d_{at} = (37 \times d_{human})/6$, the corresponding dose of QYPD for rats is 154.2 mg/kg per day. Previous reports show that there is no toxic reaction in rats treated with 4,000 mg/kg QYPD for 26 weeks (Wang et al., 2018).

| Gene symbol | Gene bank ID | Forward primer | Reverse primer | Product size (bp) |
|-------------|-------------|----------------|---------------|------------------|
| Wnt1        | NM_001105714 | TCTTCTGCGGA    | ATACCACAGGG   | 124              |
| Ctnnb1      | NM_053587   | ATACATTGGGCC   | GACAGACAGC    | 104              |
| Tgfb1       | NM_021578   | AGGGCTACCAT    | GACAGACCTTC   | 168              |
| Smad2       | NM_001277450| GCCAACCCTC     | TCTGTGGCTCC   | 164              |

Wnt1, Wnt family member 1; Ctnnb1, catenin beta 1; Tgfb1, transforming growth factor beta 1.
Therefore, the low dosage of Qishen Yiqi dripping pill and HQYDP groups were orally administered QYDP (Tasly Pharmaceutical Group Co., Ltd., Tianjin, China) at 150 and 300 mg/kg/day by gavage, respectively. The DM group and normal control (NC) group were given an equal volume of saline. All rats were anesthetized via intraperitoneal injection of sodium pentobarbital (150 mg/kg) and then killed at the eighth week after treatment. The kidneys were immediately collected.

**Blood Sample Analysis and Sample Preparation**

After 6 h of fasting, blood was collected through the intraorbital retrobulbar plexus. For 24-h urine collection, the rats were housed in individual metabolic cages at the end of the 8-week treatment. Urine was centrifuged at 3,000 × g for 10 min at room temperature. Blood glucose, serum creatinine, blood urea nitrogen (BUN), and urine albumin levels were measured with a Beckman biochemical analyzer (Counter, AU5800, Germany).

**Histological Examination of the Kidney**

Kidneys were fixed in formalin and then embedded in paraffin. Five-micrometer-thick sections were stained with periodic–acid Schiff (PAS) and Masson’s trichrome stain. Using PAS staining, the glomerular score of each rat was calculated as the arithmetic mean of 60 glomeruli (400× magnification) (el Nahas et al., 1987). The tubulointerstitial damage score (dilatation, atrophy, hyaline in the tubular lumen, visible detachment of tubular cells, interstitial infiltration of mononuclear cells, and interstitial fibrosis) was assessed as previously described (Piecha et al., 2008).

**RNA Extraction and Gene Array Analysis**

Total RNA was extracted from the kidney cortex using a mirVana™ RNA isolation kit (Ambion, São Paulo, Brazil).
Double-stranded complementary DNA (cDNA) was synthesized from RNA. Then, biotinylated cDNA was hybridized to an Affymetrix GeneChip Rat Gene 2.0 ST whole transcript-based array (Affymetrix Technologies, Santa Clara, CA, United States). Genes that had a \( p \)-value < 0.05 and a fold change > 1.5 were selected. The data obtained have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus database (accession number GSE134072).

The Database for Annotation, Visualization, and Integrated Discovery web-based software tool was used to perform gene ontology (GO) enrichment analysis. In addition, pathway enrichment analysis based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used to identify significant pathways.

**Real-Time PCR Analysis**

cDNA was synthesized using SuperScript II reverse transcriptase (Life Technologies, Carlsbad, CA, United States). Real-time PCR was performed using a Real-time PCR Mater Mix Kit (Applied Biosystems, Foster City, CA, United States) and ABI SYBR Mix (Applied Biosystems, Foster City, CA, United States). The specific primers are listed in Table 1. Data were analyzed using the \( \Delta \Delta C_t \) method with glyceraldehyde 3-phosphate dehydrogenase as the constitutive marker.

**Immunohistochemistry for Transforming Growth Factor-\( \beta \), \( \beta \)-Catenin, and Smad2 in the Kidney**

Five-micron-thick renal sections were deparaffinized, rehydrated, and immersed in phosphate-buffered saline. Then, the sections were stained with anti-TGF-\( \beta \) (1:100, Santa Cruz Biotechnology, Dallas, TX, United States), anti-\( \beta \)-catenin (1:100, Santa Cruz Biotechnology, Dallas, TX, United States), and anti-Smad2 (1:100, Santa Cruz Biotechnology, Dallas, TX, United States) antibodies at 4°C overnight. Tissue sections were then incubated with a horseradish peroxidase-conjugated secondary antibody (1:2,000, Santa Cruz Biotechnology, Dallas, TX, United States) antibodies at 4°C overnight. Immuno-labeling was visualized with 0.05% diaminobenzidine.
A digital microscope (Nikon, Tokyo, Japan) was used to analyze sections at 400× magnification to identify positive cells.

**Western Blot Analysis**

Kidneys were homogenized in radioimmunoprecipitation assay buffer (Millipore, Bedford, MA, United States) to obtain total proteins. Total protein (30 µg) was loaded in 10% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, United States). Then, the membranes were blocked in Tris-buffered saline with skim milk for 1 h, followed by overnight incubation at 4°C with rabbit anti-TGF-β (1:1,000, Abcam, Cambridge, United Kingdom), rabbit anti-β-catenin (1:1,000, Abcam, Cambridge, United Kingdom), rabbit anti-smad2 (1:1,000, Abcam, Cambridge, United Kingdom), rabbit anti-collagen I (1:1,000, Abcam, Cambridge, United Kingdom), rabbit anti-α-smooth muscle actin (α-SMA, 1:1,000, Abcam, Cambridge, United Kingdom), or rabbit anti-fibronectin (FN, 1:1,000, Abcam, Cambridge, United Kingdom) antibody. After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (1:3,000, Santa Cruz Biotechnology, Santa Cruz, CA, United States) for 2 h at room temperature. After another wash, membranes were developed using an enhanced chemiluminescence (Cell Signaling Technology, Danvers, MA, United States) assay. Bound proteins were scanned with an Epson V300 scanning system (Epson, Suwa, Japan). The density of protein bands was quantified with AlphaEaseFC software (Alpha Innotech, San Leandro, CA, United States). The housekeeping protein β-actin (1:3,000, Abcam, Cambridge, United Kingdom) was used for normalization.

**Statistical Analysis**

Data are shown as the mean ± SD. Statistical analyses were calculated with two-way ANOVA followed by Tukey's post hoc test among the four groups. The Student's t-test was used to analyze differences between different groups. GraphPad Prism 6 (GraphPad Software Inc., CA, United States) was used for data analysis. P < 0.05 was considered to indicate significance.
RESULTS

Ultra-Performance Liquid Chromatography Analysis of Qishen Yiqi Dripping Pill
Six main QYDP components were confirmed by UPLC analysis. The UV detector for UPLC analysis was set to 203 nm according to the standard maximum absorption rate. The UPLC analysis of QYDP is presented in Figures 1A,B. The six main QYDP constituents are (1) salvianic acid (3.942 mg/g), (2) calycosin glycoside (0.2656 mg/g), (3) notoginseng R1 (0.618 mg/g), (4) Ginsenoside Rg1 (2.204 mg/g), (5) Ginsenoside Re (0.4484 mg/g), and (6) Ginsenoside Rb1 (1.9 mg/g).

Effect of Qishen Yiqi Dripping Pill on Body Weight and Fasting Blood Glucose
The DM group showed decreased body weight compared with that of the NC group ($p < 0.01$, Figure 2A). QYDP did not change the body weight of diabetic rats ($p > 0.05$, Figure 2A). The DM group had higher fasting blood glucose ($p < 0.01$, Figure 2B) than the control group. QYDP did not reduce fasting blood glucose in diabetic rats ($p > 0.05$, Figure 2B).

Effect of Qishen Yiqi Dripping Pill on Renal Function Parameters
Serum creatinine, BUN, and 24-h urinary albumin levels were significantly increased in the DM group ($p < 0.01$, Figures 2C–E). QYDP treatment decreased serum creatinine, BUN, and 24-h urinary albumin levels ($p < 0.01$, Figures 2C–E). These results suggest that QYDP moderated renal function in diabetic rats.

Effect of Qishen Yiqi Dripping Pill Treatment on Histopathological Changes in Renal Tissue
With PAS staining, both a higher glomerular lesion score and higher tubulointerstitial lesion score were observed in diabetic rats compared with normal rats ($p < 0.01$, Figures 3A,C). Glomerular hypertrophy and tubulointerstitial changes were mostly prevented by QYDP treatment ($p < 0.01$, Figures 3A,C). Further examination of Masson’s-stained renal tissue sections showed that the diabetic rats presented more collagen fibers in the glomerular mesangium and basement membrane ($p < 0.01$, Figures 3B,D). QYDP treatment significantly attenuated collagen deposition ($p < 0.01$, Figures 3B,D).

Gene Array, Pathway, Gene Ontology, and Network Analysis Results in the High Dosage of QishenYiqi Dripping Pill Group vs. the Diabetes Mellitus Group
We identified 316 significantly differentially expressed genes, including 189 upregulated genes and 127 downregulated genes in the HQYDP group, compared with the DM group (fold change > 1.5, $p < 0.05$). To systematically identify biological connections among the differentially expressed genes and
to identify pathways associated with the effect of QYDP on the kidney, we performed GO and KEGG pathway analyses. Figure 4 and Table 2 show the top five terms in three categories, biological processes, cellular components, and molecular functions. Among the biological process ontology results, the major GO terms affected by QYDP were negative regulation of extrinsic apoptotic signaling pathway via death domain receptors, positive regulation of ERK1 and ERK2 cascade, response to a drug, liver regeneration, and regulation of the apoptotic process. Figure 5 and Table 3 show the

### Table 2 | Top 5 enriched GO terms in each catalog associated with differentially expressed genes in HQYDP group vs. DM group.

| term ID     | term name                                           | count | p value             | fold enrichment | involved genes                     | catalog                        |
|-------------|-----------------------------------------------------|-------|---------------------|-----------------|------------------------------------|--------------------------------|
| GO:1902042  | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 6     | $1.29 \times 10^{-5}$ | 18.828          | ICAM1, FGG, FGA, SFRP2, FGB, HMOX1 | biological processes           |
| GO:0070374  | positive regulation of ERK1 and ERK2 cascade        | 12    | $8.42 \times 10^{-5}$ | 4.454           | ICAM1, FGG, FGA, C10TFN3, FGB, SEMA7A, P2RY1, PYCARD, TREM2, GPNMB, SLAMF1, TGFBI | biological processes           |
| GO:0042493  | response to drug                                    | 21    | $8.64 \times 10^{-5}$ | 2.746           | ICAM1, SLC2A1, MAT2A, LGALS1, IL1RN, GGH, CTNN1, ABCA1, SLC01A6, TGFBI, CTNNB1, CDKN1A, TNFRSF11B, ACE, HTR1B, PLN2, SFRP2, ABCB1B, TGFBI, FAS, MYC | biological processes           |
| GO:0097421  | liver regeneration                                  | 7     | $1.36 \times 10^{-4}$ | 8.786           | FGA, HMOX1, CLDN1, RGN, FAS, MYC, TGFBI | biological processes           |
| GO:0042981  | regulation of apoptotic process                      | 11    | $1.84 \times 10^{-4}$ | 4.467           | TNFRSF1B, TNFRSF11B, BMP1, SFRP2, PYCARD, CIDEA, APAF1, FAS, GDF15, MYC, CTNNB1 | biological processes           |
| GO:0005615  | extracellular space                                 | 47    | $1.24 \times 10^{-5}$ | 2.496           | GC, LTBP4, BTC, UMOD, TGFBI, LIF, WNT1, FGG, TNFRSF1B, WNT4, ACE, FGA, C10TFN3, FGB, SEMA7A, PP1R1A, VNN1, TFF3, SERPINB12, FAS, EGFL7C1, ANGPTL4, SPP1, SELP, ICAM1, BDP1, PLAG1G5, LOC360919, C4B, LGALS1, IL1RN, KING1L1, AXL, GGH, CPXM2, HILPDA, MEGF8, AFM, DKK1, SFRP2, LIFG, ACE2, ANXA13, IGFBP1, GDF15, PON3 | biological processes           |
| GO:0005887  | integral component of plasma membrane               | 37    | $6.76 \times 10^{-5}$ | 2.745           | LOC361914, CLDN4, CADM2, SLC15A2, TSPAN4, KCNJ10, ABCA1, ATP12A, KCNJ13, INSR, TNFRSF1B, SLC01A1, TNFRSF11B, HTR1B, SLC29A8, FAS, GPNMB, SLC22A2, ICAM1, SLC8A1, SLC8A13, SLC22A22, NRP2, SLC10A5, SLC7A13, SLC01A6, SLC7A12, SLC26A4, SEMA6A, FOLH1, SLC16A4, SLC16A7, GRM8, SLC26A7, CLDN1, SLC13A1, STEAP1 | biological processes           |
| GO:0007062  | extracellular exosome                               | 67    | $2.55 \times 10^{-6}$ | 1.770           | PVR, GDA, SLC15A2, LTBP4, CTNNB1, SLC1A4, PKRRA2A, TUBB6, VNN1, RHOB, FAS, ATP6V0D2, SLC22A2, ICAM1, HIST1H15B, C4B, CTNNB1, ATP12A, KCNJ13, NR1D1, OCT3, SERPINB12, FAS, EGFL7C1, ANGPTL4, SPP1, SELP, ICAM1, BDP1, PLAG1G5, LOC360919, C4B, LGALS1, IL1RN, KING1L1, AXL, GGH, CPXM2, HILPDA, MEGF8, AFM, DKK1, SFRP2, LIFG, ACE2, ANXA13, IGFBP1, GDF15, PON3 | biological processes           |
| GO:0016323  | basolateral plasma membrane                         | 14    | $9.07 \times 10^{-6}$ | 4.727           | SLC8A1, CASR, NK2D, SLC22A22, LUMOD, CTNNB1, KCNJ10, ATP6V1B1, ATP12A, CTNNB1, SLC01A1, SLC26A7, P2RY1, SLC22A2 | cellular components            |
| GO:0072562  | blood microparticle                                 | 10    | $4.90 \times 10^{-5}$ | 5.923           | GC, FGG, AFM, FGA, LOC691828, C4B, FGB, GNG1L1, TGFBI, ANGPTL4 | cellular components            |
| GO:0015175  | neutral amino acid transmembrane transporter activity | 4     | 0.0017             | 16.453          | SLC1A4, LOC361914, SLC7A13, SLC7A12 | molecular function            |
| GO:0004180  | carboxypeptidase activity                           | 4     | 0.0020             | 15.485          | FOLH1, ACE, ACE2, CPXM2 | molecular function            |
| GO:0000978  | RNA polymerase II core promoter proximal region sequence-specific DNA binding | 14    | 0.0024             | 2.663           | AR, ELF3, SP11, SMAD3, SMAD2, MYBL1, FOXP2, GOM1, NR1D1, OVO1, TEF, TGFBI, POLG1F1, MYC | molecular function            |
| GO:0005160  | transforming growth factor beta receptor binding integrin binding | 5     | 0.0037             | 7.835           | BMP1, SMAD3, SMAD2, GDF15, TGFBI | molecular function            |
| GO:0005178  | transforming growth factor beta receptor binding integrin binding | 7     | 0.0041             | 4.607           | ICAM1, CASR, SEMA7A, TSPAN4, MEGF8, GPNMB, SYK | molecular function            |
top 10 pathways identified via KEGG pathway analysis affected by QYDP, including the FoxO signaling pathway, signaling pathways regulating pluripotency of stem cells, TGF-β signaling pathway, colorectal cancer, Human T-cell leukemia virus, type 1 infection, Wnt signaling pathway, pathways in cancer, Hippo signaling pathway, proteoglycans in cancer, and prostate cancer.

By using String online software, the 316 differentially expressed genes were mapped in a network. Two hundred ninety-six nodes with 350 joint-edges were featured in this map.
(Figure 6). Fifteen nodes with no less than 10 joint-edges were considered important functional molecules in QYDP-treated kidneys because they accounted for 66.8% of the function of all genes. Among these 15 nodes, glyceraldehyde-3-phosphate dehydrogenase, myelocytomatosis oncogene, catenin β1 (Ctnnb1), transforming growth factor β1 (Tgfb1), serum glucocorticoid regulated kinase 1, spleen tyrosine kinase, cyclin-dependent kinase inhibitor 1A, mitogen-activated protein kinase 4, angiotensin I converting enzyme, and intercellular adhesion molecule 1 were ranked in the top 10.

Real-Time PCR Validation Results

Because the TGF-β signaling pathway and Wnt signaling pathway were among the top-ranked KEGG pathways associated with differentially expressed genes in the HQYDP group vs. the DM group, we selected several genes in these two pathways to assay expression among the four different groups using quantitative PCR. We found that diabetic rats had significantly increased Wnt family member 1 (Wnt1), Ctnnb1, Tgfb1, and Smad2 expression in the kidney (p < 0.01, Figure 7) compared with that in the control group. QYDP treatment reduced Wnt1, Ctnnb1, Tgfb1, and Smad2 expression in diabetic kidneys (p < 0.01, Figure 7). These results were consistent with the microarray results.

Effect of Qishen Yiqi Dripping Pill on Transforming Growth Factor-β, β-Catenin, and Smad2 Expression in the Kidney Determined by Immunohistochemistry Staining

Immunohistochemistry analyses showed that in the DM group, TGF-β, β-catenin, and Smad2 immunoreactivity was higher than in the NC group in the glomeruli, tubuli, and interstitial areas (p < 0.01, Figure 8). QYDP treatment inhibited TGF-β, β-catenin, and Smad2 levels in the glomerular and tubulointerstitial areas of diabetic kidneys (p < 0.01, Figure 8).

Effect of Qishen Yiqi Dripping Pill on the Protein Levels of Transforming Growth Factor-β, β-Catenin, Smad2 and Fibrotic Markers in the Kidney

Similar to the immunohistochemical analyses, an increase in TGF-β, β-catenin, and Smad2 was observed in diabetic rat kidneys (p < 0.01, Figure 9). Treatment with QYDP significantly decreased TGF-β, β-catenin, and Smad2 expression (p < 0.01, Figure 9). The expression levels of the fibrotic markers, collagen I, α-SMA, and FN were upregulated in diabetic rat kidneys.
FIGURE 7 | Effect of QYDP on Wnt1, Ctnnb1, Tgfb1, and Smad2 expression determined by qPCR. Values are mean ± SD (n = 6); **p < 0.01 compared with NC group; ##p < 0.01 compared with DM group. QYDP, Qishen Yiqi dripping pill; NC, normal control; DM, diabetes mellitus; LQYDP, low dose of Qishen Yiqi dripping pill; HQYDP, high dose of Qishen Yiqi dripping pill; Wnt1, Wnt family member 1; Ctnnb1, catenin beta 1; Tgfb1, transforming growth factor beta 1.

(p < 0.01, Figure 9). QYDP treatment reversed the increases of these fibrotic markers (p < 0.01, Figure 9).

DISCUSSION

In this study, our data show that both the low and high QYDP dosage reduced serum creatinine, BUN, and 24-h urinary albumin and moderated kidney hypertrophy and renal histology in diabetic rats. No significant dosage-dependent effect was observed. The possible reason might be that the high dosage exceeds the maximum efficacy. Furthermore, we observed a significant downregulation of collagen I, α-SMA, and FN in QYDP-treated diabetic rats. Overall, QYDP moderated kidney function and renal fibrosis in diabetic rats. QYDP includes Radix Astragali (A. penduliflorus Lam.), redroot sage (S. miltiorrhiza Bunge), pseudoginseng (P. pseudoginseng Wall.), and fragrant rosewood (D. odorifera T.C. Chen). Astragalosides, which is an active ingredient of Radix Astragali, have a potent antioxidative effect and inhibit high glucose-induced mesangial cell proliferation in vitro (Sun et al., 2014; Chen et al., 2016). Radix Astragali significantly reduces oxidative activity in diabetic rat kidneys (Chen et al., 2016). Two major isoflavonoids in Radix Astragali have inhibitory effects on AGE-induced endothelial cell apoptosis (Tang et al., 2011). Redroot sage extracts have a renoprotection effect in streptozotocin-induced diabetic rats (Yin et al., 2014), ameliorated renal function, and reduced TGF-β1 (Liu et al., 2005) and collagen IV (Lee et al., 2011).

Without reducing blood glucose, QYDP can moderate renal function in diabetic rats. This indicates that QYDP has direct beneficial effects on the kidney rather than indirect effects through moderating hyperglycemia. We further performed microarray gene expression profile analysis to determine the mechanism underlying the effect of QYDP on the kidneys of diabetic rats. Then, pathway analysis of the genes that were differentially expressed in the HQYDP-treated group compared with the DM group was performed. From this analysis, we found that the Wnt signaling pathway was in the top 10 pathways. The Wnt signaling pathway diversifies into two branches: the canonical Wnt pathway (the β-catenin pathway) and the non-canonical Wnt pathway. In this study, we found
that QYDP reduced Wnt1 and Ctnnb1 expression in diabetic rats. Additionally, immunostaining analysis and western blotting showed that QYDP reduced β-catenin protein expression. In gene interaction analysis, Ctnnb1 was centrally located among all the differentially expressed genes in the HQYDP-treated group compared with those in the DM group. In CKD rats, QYDP also inhibited β-catenin expression (Zhou et al., 2016). The Wnt/β-catenin pathway is involved in cellular growth and differentiation in DN (Xiao et al., 2013). In kidneys of both type 1 and 2 diabetic models, the Wnt pathway is activated abnormally (Zhou et al., 2012). This activation of Wnt/β-catenin contributes to proteinuria (Kato et al., 2011), podocyte dysfunction (Dai et al., 2009), glomerulosclerosis, and renal interstitial fibrosis (He et al., 2009). In vivo and in vitro, overexpression of either Wnt1 or stabilized β-catenin leads to podocyte dysfunction (Dai et al., 2009). Blockade or knockout of Wnt/β-catenin protects against the development of podocyte lesions and albuminuria (Dai et al., 2009). Thus, QYDP treatment may alleviate kidney dysfunction by inhibiting the Wnt/β-catenin pathway.

In addition, pathway analysis showed that the TGF-β signaling pathway ranked third among all pathways affected by QYDP in the kidneys. Immunostaining analysis and western blot analysis showed that QYDP reduced TGF-β expression. TGF-β is an essential mediator that stimulates glomerular ECM formation in DN (Yamamoto et al., 1994). Hyperglycemia leads to TGF-β activation. Chronic inhibition of TGF-β using neutralizing monoclonal antibody in db/db mice prevents glomerulosclerosis and renal dysfunction (Ziyadeh et al., 2000). Zhou et al. (2016) found that QYDP inhibits TGF-β1-induced β-catenin upregulation in the cytoplasm but does not affect Smad2 and Smad3 phosphorylation and Smad4 or Smad7 expression in normal kidney proximal tubular (NRK52E) cells. However,
in our study, gene interaction analysis showed that Smad2, Smad3, and Tgfb1 were in the central position among all the differentially expressed genes in the HQYDP-treated group compared with the DM group. QYDP reduced Tgfb1 and Smad2 expression and inhibited TGF-β and Smad2 protein expression in diabetic kidneys. The reason for the different results in NRK52E cells and diabetic rats might be the different circumstances in vivo and in vitro. Unlike diabetic rats, NRK52E cells were used by Zhou et al. (2016). The Smad signaling pathway plays an important role in the TGF-β1-stimulated accumulation of ECM. TGF-β1/Smad signaling is a critical pathway for the development of renal fibrosis. TGF-β1 activates Smad2 and Smad3 phosphorylation, and then, phospho-Smad2/3 binds to Smad4 to form hetero-oligomeric complexes (Meng et al., 2015). These complexes translocate to the nucleus to regulate the transcription factors of other genes related to kidney fibrosis (Massague and Chen, 2000). Hence, QYDP might inhibit TGF-β1/Smad signaling to improve kidney function in diabetic rats.

**CONCLUSION**

In summary, this study reveals that QYDP significantly attenuates kidney function and renal fibrosis. Our study is the first to show that QYDP moderates kidney function by inhibiting the Wnt/β-catenin pathway and TGF-β/Smad signaling in diabetic rats (Figure 10). These results provide a basis for the treatment of DN patients in the future. Further in vitro research is still required to elucidate the mechanistic details of QYDP protection against DN.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**ETHICS STATEMENT**

The animal study was reviewed and approved by this study was conducted in strict accordance with the recommendations and the approval of the Animal Care Committee of the Peking Union Medical Hospital Animal Ethics Committee (Project XHDW-2015-0051, 15 February 2015), and all efforts were made to minimize suffering.

**AUTHOR CONTRIBUTIONS**

XX designed the experiments and contributed reagents and materials. QZ, JZ, TW, and XW conducted the experiments. MY, ML, and FP analyzed the data. QZ wrote the manuscript. All authors have read and approved the article.
FUNDING

This work was supported by grants from National Key R&D Program of China (2017YFC1309603), National Natural Science Foundation of China (Nos. 81870579, 81870545, 81170736, and 81570715), Beijing Natural Science Foundation (7202163 and 7172169), Beijing Municipal Science & Technology Commission (Z201100005520011), Beijing Dongcheng District Outstanding Talent Funding Project (2019DCT-M-05), National Key Research and Development Program of China (2016YFA0101002 and 2018YFC2001100), Medical Epigenetics Research Centre, Chinese Academy of Medical Sciences (2017PT31036 and 2018PT31021), the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences (Nos. 2017PT32020 and 2018PT32001), National Natural Science Foundation for Young Scholars of China (No. 81300649), China Scholarship Council (2018PT31021), and Fundamental Research Funds for the Central Universities, and Scientific Activities Foundation for Selected Returned Overseas Professionals of Human Resources and Social Security Ministry, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS2017-12M-1-008).

ACKNOWLEDGMENTS

We are very grateful to Beijing Compass Biotechnology Company for excellent technical assistance with the microarray experiments.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2020.613324/full#supplementary-material

REFERENCES

Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes Metab. Res. Rev. 40, 405–412. doi: 10.2337/diabrev.40.4.405

Brownlee, M., Cerami, A., and Vlassara, H. (1988). Advanced glycoylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315–1321. doi: 10.1056/nejm198805193182007

Chen, X., Wang, D. D., Wei, T., He, S. M., Zhang, G. Y., and Wei, Q. L. (2013). The protective effects of Salvia miltiorrhiza on rats with streptozotocin diabetes and its mechanism. Zhong Xi Yi Jie He Xue Bao 3, 459–462. doi: 10.3736/jcm20059610

Marianap, M. M. (2012). Signaling mechanisms in the regulation of renal matrix metalloproteinases in diabetes. Exp. Diabetes Res. 2012:749812. doi: 10.1155/2012/749812

Massague, J., and Chen, Y. G. (2000). Controlling TGF-beta signaling. Genes Dev. 14, 627–644.

Meng, X. M., Tang, P. M., Li, J., and Lan, H. Y. (2015). TGF-beta/Smad signaling in renal fibrosis. Front. Physiol. 6:82. doi: 10.3389/fphys.2015.00082

Nelson, R. G., Bennett, P. H., Beck, G. J., Tan, M., Knowler, W. C., Mitch, W. E., et al. (1996). Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N. Engl. J. Med. 335, 1636–1642. doi: 10.1056/nejm19961283352023

Piecha, G., Kokeny, G., Nakagawa, K., Koleganova, N., Geldyev, A., Berger, I., et al. (2008). Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am. J. Physiol. Renal Physiol. 294, F748–F757. doi: 10.1152/ajprenal.00220.2007

Sun, L., Li, W., Li, W., Xiong, L., Li, G., and Ma, R. (2014). Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-kappab pathway under high glucose conditions. Int. J. Mol. Med. 34, 167–176. doi: 10.3892/ijmm.2014.1741

Tang, D., He, B., Zheng, Z. G., Wang, R. S., Gu, F., Duan, T. T., et al. (2011). Inhibitory effects of two major isoflavonoids in Radix Astragali on high glucose-induced mesangial cells proliferation and AGEs-induced endothelial cells apoptosis. Planta Med. 77, 729–732. doi: 10.5555/0-120-150628

Wang, G., Zheng, C., Wang, Y., Hao, R., Xu, H., Pan, L., et al. (2019). “Study on the toxicity and toxicokinetics of Qishen Yiqi dropping pills after repeated intragastric administration for 26 weeks in rats,” in Proceedings of the Annual Conference on Toxicology and safety evaluation of traditional Chinese medicine and natural drugs of Chinese society of Toxicology, Berlin.

Williams, R., Karuranga, S., Malanda, R., Saeedi, P., Beig, A., Besancon, S., et al. (2020). Global and regional estimates and projections of diabetes-related health expenditure: results from the international diabetes federation diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 162:108072. doi: 10.1016/j.diabret.2020.108072

Xiao, L., Wang, M., Yang, S., Liu, F., and Sun, L. (2013). A glimpse of the pathogenetic mechanisms of Wnt/beta-catenin signaling in diabetic nephropathy. Biomed. Res. Int. 2013:987064. doi: 10.1155/2013/987064

Yamamoto, Y., Noble, N. A., Miller, D. E., and Border, W. A. (1994). Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 45, 916–927. doi: 10.1038/ki.1994.122
Yin, D., Yin, J., Yang, Y., Chen, S., and Gao, X. (2014). Renoprotection of Danshen Injection on streptozotocin-induced diabetic rats, associated with tubular function and structure. J. Ethnopharmacol. 151, 667–674. doi: 10.1016/j.jep.2013.11.025

Yongbin Chen, Y. W. (2011). Curative effect of Qishenyiqi Drop Pills on early diabetic nephropathy. Chinese Gen. Practice 14, 520–522.

Zhou, T., He, X., Cheng, R., Zhang, B., Zhang, R. R., Chen, Y., et al. (2012). Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy. Diabetologia 55, 255–266.

Zhou, Z., Hu, Z., Li, M., Zhu, F., Zhang, H., Nie, J., et al. (2016). QiShenYiQi attenuates renal interstitial fibrosis by blocking the activation of beta-catenin. PLoS One 11:e0162873. doi: 10.1371/journal.pone.0162873

Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-De La Cruz, M. C., Hong, S. W., Isono, M., et al. (2000). Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 97, 8015–8020. doi: 10.1073/pnas.120055097

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Xiao, Zheng, Li, Yu, Ping, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.